Foundation Medicine, Inc. has announced FDA approval for FoundationOne® Liquid CDx as a companion diagnostic for Itovebi™ (inavolisib) when used with palbociclib (Ibrance®) and fulvestrant. This therapy, developed by Genentech,…
Paige, a leader in next-generation AI technology, has announced that its foundation models will be showcased by Microsoft at the HLTH 2024 conference in Las Vegas. On October 21st, Matt…
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced the acceptance of four abstracts for the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that it presented data demonstrating the effectiveness of sebetralstat in reducing anxiety during hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF)…
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company focused on developing first-in-class logic-gated cell therapies to selectively target tumor cells while protecting healthy cells, has announced that six…
Exact Sciences Corp. (NASDAQ: EXAS), a prominent provider of cancer screening and diagnostic solutions, has announced that the U.S. Food and Drug Administration (FDA) has approved its next-generation multitarget stool…
DeepCure, a therapeutics company leveraging AI to discover innovative drugs for inflammation and immune diseases, today announced that it will present data demonstrating that its selective BRD4 (BD2) inhibitor, DC-9476,…
Ginkgo Bioworks, Inc. is establishing a premier platform for cell programming and biosecurity, while Virica Biotech Inc. specializes in enhancers for scaling viral vectors and cell and gene therapies. The…
Science Exchange, a top provider of SaaS solutions for life sciences procurement and supplier management, has announced its acquisition by Waud Capital Partners, a private equity firm focused on growth…
MATTER, a leading healthcare incubator and innovation hub, has launched the inaugural accelerator program for the Paratus Digital Health Hub. Paratus is part of the Biomedical Advanced Research and Development…
Iambic Therapeutics, a clinical-stage biotech company harnessing its AI-driven discovery platform, has been named to the 2024 Endpoints News list of “Biotech’s Most Promising Startups.” This annual award highlights innovative…
GE HealthCare announced that the FDA has approved Flyrcado™ (flurpiridaz F 18) injection, a groundbreaking PET myocardial perfusion imaging (MPI) agent, for detecting coronary artery disease (CAD). Flyrcado offers higher…